MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

1
Player Avatar mconway31 (< 20) Submitted: 1/24/2011 9:32:56 AM : Outperform Start Price: $5.57 MNKD Score: -72.12

if there new diabetes inhaler gets approved for sale next year watch this stock take off

Report this Post 1 Comment
Member Avatar nottobetrusted (< 20) Submitted: 3/15/2012 6:12:52 AM
Recs: 0

http://www.sfvbj.com/news/2012/mar/13/valencia-electronics-manufacturer-acquired-singapo/

Proceeds of sale may be used to keep MNKD afloat until (much anticipated) approval.
Bump? This, plus the fact that cash burn has been greatly reduced, should help.

Report this Post

Featured Broker Partners


Advertisement